
## Lorenzo Tofani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2378130/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19. Rheumatology, 2022, 61, 1600-1609.	1.9	53
2	Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition. Journal of Scleroderma and Related Disorders, 2022, 7, 24-32.	1.7	25
3	The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2096403.	2.7	21
4	Ultra-rapid brain uptake of subcutaneous sumatriptan in the rat: Implication for cluster headache treatment. Cephalalgia, 2020, 40, 330-336.	3.9	13
5	Linezolid extracorporeal removal during haemodialysis with high cut-off membrane in critically ill patients. International Journal of Antimicrobial Agents, 2015, 46, 465-468.	2.5	11
6	Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience. Autoimmunity Reviews, 2021, 20, 102981.	5.8	9
7	Lung Ultrasound B-Lines in the Evaluation of the Extent of Interstitial Lung Disease in Systemic Sclerosis. Diagnostics, 2022, 12, 1696.	2.6	8
8	Serum Organ-Specific Anti-Heart and Anti-Intercalated Disk Autoantibodies as New Autoimmune Markers of Cardiac Involvement in Systemic Sclerosis: Frequency, Clinical and Prognostic Correlates. Diagnostics, 2021, 11, 2165.	2.6	7
9	Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110336.	2.7	6
10	Regional Citrate Anticoagulation and Systemic Anticoagulation during Pediatric Continuous Renal Replacement Therapy: A Systematic Literature Review. Journal of Clinical Medicine, 2022, 11, 3121.	2.4	6
11	Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases. Journal of Clinical Medicine, 2020, 9, 1310.	2.4	5
12	Rehabilitation of the face and temporomandibular joint in systemic sclerosis. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110201.	2.7	4
13	Validation of END-of-life ScorING-system to identify the dying patient: a prospective analysis. BMC Anesthesiology, 2020, 20, 63.	1.8	1
14	Real-life isoniazid and rifampicin plasma concentrations in children: a tool for therapeutic drug monitoring of tuberculosis. BMC Infectious Diseases, 2021, 21, 1087.	2.9	1
15	The importance of identifying the direction of the association between preoperative inflammatory mediators and postoperative delirium. Comment on Brit J Anaesth 2021; 127: 424–434. British Journal of Anaesthesia, 2021, , .	3.4	1
16	Risk of malignancy and biologic therapy in rheumatic inflammatory diseases: A single-center experience. Rheumatology and Immunology Research, 2020, 1, 39-45.	0.8	0